Contact this trialFirst, we need to learn more about you.
Lorlatinib for Lung Cancer
Recruiting3 awardsPhase 4
Orange, California
This trial aims to continue providing lorlatinib to patients who are still benefiting from it. Lorlatinib is a medication that helps stop cancer cells from growing. The trial will also collect more safety data to better understand any side effects. Lorlatinib is used to treat non-small-cell lung cancer with ALK or ROS1 rearrangement, and it has been studied to assess its safety and effectiveness.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service